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Haplo
HSCT
MRD
HSCT
UD
HSCT
N 31 47 63
Age: Median (range) 61 (55-73) 62 (55-71) 64 (57-71)
HCT-comorbidity Index > 2 62% 47% 47%
Myeloid Malignancies 49% 47% 54%
High/Very high disease
Risk index (DRI)
35% 35% 27%
Graft Failure 1 0 0
100 days 3-4 aGVHD 10% 15% 25%
1 Year severe cGVHD 0% 15% 15%
Overall NRM 10% 11% 37%
Overall relapse 19% 29% 25%
PFS 62% 61% 42%
PFS w/o cGVHD 62% 61% 35%
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registry screening policy. He was declared medically ﬁt to
donate by G-CSF mobilized PBSC harvest, and commenced a
4-day course of recombinant glycosylated G-CSF at 10mg/kg
daily.
Shortly after administration of the third dose, he developed
frank hematuria. The fourth dose was omitted and PBSC
harvest occurred the following day. On the day of collection,
his creatinine had increased to 148 umol/l and quantitative
urinalysis showed frank hematuria and heavy proteinuria
(4.1g/day). He was reviewed by a nephrologist and a pre-
sumptive diagnosis of IgA nephropathy (IgAN) was made.
Renal biopsy features conﬁrmed this. Biochemical indices
resolved although proteinuria and microscopic hematuria
persisted ﬁve months later.
We encountered a similar case more recently, where a
28-year-old Caucasian male donor with an unremark-
able medical history developed hematuria after 3 doses
of G-CSF. A fourth dose was nevertheless administered
as the symptoms were not reported at the time. On
the day of collection, his creatinine was 77 umol/l and
urinalysis showed heavy hematuria but no proteinuria.
Five days post donation his renal imaging was normal
but quantitative urinalysis revealed heavy proteinuria
(5g/day). He was reviewed by a nephrologist two
weeks later and his proteinuria had improved to
approximately 0.5g/day. A presumptive diagnosis of
IgAN was suggested but a renal biopsy was not
deemed necessary given the improvement of his lab-
oratory indices.
In summary, these cases illustrate a proven and prob-
able pre-existing IgAN exacerbated by G-CSF. IgAN is a
common form of glomerulonephritis seen worldwide.
The use of G-CSF has previously been linked to he-
maturia and 2 case reports of proven IgAN have been
reported to date. The Serious Events and Adverse Re-
actions database held by the World Marrow Donor
Association (WMDA) reports 1 episode of unexplained
hematuria in G-CSF mobilized donors. This is likely an
underestimate particularly when cases present only
with asymptomatic proteinuria or microscopic hematu-
ria. We would urge all donor registries to report any
cases to the WMDA. We would also recommend the
introduction of urinalysis as part of the medical work-
up in all HSC donors and the follow-up management as
shown in Figure 1.Figure.387
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of allo HSCT. Recently it has been shown that a hap-
loidentical donor could be a valid option to perform allo
HSCT given adapted immunosuppression is used. Notably
the use of PT-HDCy, after T-replete HSCT following reduced
intensity (RIC) or non-myeloablative (NMAC) conditioning,
has been associated with promising results. However little
data exist concerning elderly population when this popu-
lation is characterized by a lack of HLA matched sibling and
a higher incidence of severe GVHD and non-relapse
mortality.
Using this strategy we transplanted 31 patients over the age
of 55 years between 2010 and 2014 and compare their
outcome with patients of the same age transplanted in the
same period from a MRD or UD.
70% of the patients in haplo group were prepared with
Flu-TBI 2gy (NMAC) (30% received Fludarabine-Busilvex
based regimen without ATG) while all patients in other
groups received the same RIC (Fludarabine (150 mg/m2)
Busilvex (2 days) rabbit ATG (2 days)). Patients in haplo
group received post graft immunosuppression with PT-
HDCy (50 mg/kg on D 3 and 4) followed with CSA and
MMF while patients in other groups received either CSA
starting on D1.
Patients in the haplo group have a trend presenting
higher comorbidities and more severe diseases (Table). A
single graft failure related to donor anti-HLA antibodies
were noted in haplo group. Median time to 0.5x109 ANC
and 20x109platelets were respectively 21 (14-32) and 28
(14-52) days after haplo HSCT. Haplo and MRD HSCT
patients presented with a similar NRM lower than UD
patients while Haplo patients present a relapse rate in-
termediate between MRD and UD (table). Overall
outcome after haplo do not differ from MRD transplant.
There is a trend for better PFS after Haplo HSCT as
compared with UD transplant (62% vs.41%; P¼0,14)
(Figure 1). Progression-free and severe cGVHD-free sur-
vival was signiﬁcantly better after haplo HSCT (62% vs.
35%; p¼0.03) (Figure 2).
We conclude that T-replete Haplo HSCT after RIC and fol-
lowed by PT-HDCy is associated with promising results
notably as compared with UD HSCT. The low rate of severe
aGVHD and cGVHD are likely to conduct to lower compli-
cations and better quality of life. The reduction of donor
search duration and the absence of graft acquisition fees
represent potential additional beneﬁts. In this perspective,
the place of Haplo HSCT in older patients should now be
prospectively addressed.388
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ZAP70 (zeta-associated protein of 70 KDa) deﬁciency is a
fatal form of combined immunodeﬁciency that can be cured
with hematopoietic stem cell transplantation (HSCT). The
normal number of thymocytes, polyclonal CD3⁺ T cells and B
cells may require special considerations in choosing themost
effective regimen of conditioning and the type of HSCT. We
analyzed presentation and outcome of patients with ZAP70
deﬁciency who received various modalities of stem cell
transplantation.
Data on 19 patients with ZAP70 deﬁciency were exam-
ined, of whom 16 underwent HSCT in 7 different
counties. HSCT was performed by using different sources
of donor stem cells as well as various conditioning
regimens.
Most patients presented with typical repeated microbial
and fungal infections; one patient presented with lym-
phoma. Close family members appear to have a high fre-
quency of autoimmunity. Sixteen of nineteen patients
were treated with HSCT. Nine patients received a MRD
and 8/9 survived, four patients had MUD transplants and
all survived and 3 had a MMRD transplant of which only
one survived. Immune reconstitution was complete and
durable in patients who received myeloablative condi-
tioning. Lack of conditioning failed in two patients and
resulted in partial immune reconstitution in the other
patients.
Based on these data, we conclude that carriers of monoallelic
mutations in ZAP70 may be susceptible to autoimmunity.
HLAmatched donor andmyeloablative conditioning result in
superior outcome and long-term robust immune re-
constitution.389
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Background: In a previous study, we showed that relapse
prophylaxis with imatinib (IM) is feasible early after alloge-
neic HCT for treatment of Ph+ leukemia [Carpenter et al,
Blood 2007;109:2791]. The goal of the current study was to
ask whether nilotinib (NIL) might address IM resistance (IR)
or intolerance (IT) because IR leukemia might be sensitive to
NIL. Previous non-HCT trials have shown that NIL and IM
have comparable hematopoietic toxicity, but the incidence of
edema and gastrointestinal toxicity is less with NIL thanwith
IM.
